Sunshine Biopharma, Inc. (SBFM)
NASDAQ: SBFM · IEX Real-Time Price · USD
0.950
+0.143 (17.66%)
At close: Apr 26, 2024, 4:00 PM
0.990
+0.040 (4.21%)
After-hours: Apr 26, 2024, 7:59 PM EDT
Sunshine Biopharma Stock Forecast
SBFM's stock price has decreased by -98.49% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Sunshine Biopharma stock has a target of 260, which predicts an increase of 27,268.42% from the current stock price of 0.95.
Analyst Consensus: Strong Buy
* Price targets were last updated on Aug 7, 2023.
Analyst Ratings
According to 1 stock analyst, the rating for SBFM is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '24 | Apr '24 |
|---|---|---|
| Strong Buy | 1 | 1 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
| Total | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Aegis Capital | Aegis Capital | Strong Buy Initiates $260 | Strong Buy | Initiates | $260 | +27,268.42% | Aug 7, 2023 |
Financial Forecast
Revenue This Year
45.29M
from 24.09M
Increased by 87.97%
Revenue Next Year
102.00M
from 45.29M
Increased by 125.23%
EPS This Year
0.09
from -19.00
EPS Next Year
0.54
from 0.09
Increased by 488.89%
Revenue Forecast
| Revenue | 2024 | 2025 |
|---|---|---|
| High | 46.6M | 105.0M |
| Avg | 45.3M | 102.0M |
| Low | 43.5M | 98.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 |
|---|---|---|
| High | 93.5% | 131.8% |
| Avg | 88.0% | 125.2% |
| Low | 80.6% | 116.4% |
EPS Forecast
| EPS | 2024 | 2025 |
|---|---|---|
| High | 0.09 | 0.56 |
| Avg | 0.09 | 0.54 |
| Low | 0.09 | 0.52 |
EPS Growth
| EPS Growth | 2024 | 2025 |
|---|---|---|
| High | - | 506.2% |
| Avg | - | 488.9% |
| Low | - | 465.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.